Personalized Models for Cancer Research
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Biological Sample Collection.
- Who it may be relevant to
- Registry conditions: Solid Tumor, Adult. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate cancer research ranging from disease mechanisms to personalized medicine approaches that will help to realize the promise of precision medicine for oncology.
Detailed description
Researchers at the New York Stem Cell Foundation (NYSCF) Research Institute will establish a living biobank of tumor/organoids and stem cells representing individual patients diagnosed with cancer. Samples from healthy individuals (non-cancer diagnosis) or from non-disease tissue will also be collected to be used as controls in this study.
Information and biospecimens may be transferred to NYSCF by external institution or NYSCF research personnel may prospectively enroll participants to have portions of samples or cells that were (or will be) collected for reasons other than this study transferred into the biobank.
NYSCF's researchers hypothesize that the development of patient-specific models that can expand in vitro while capturing tumor complexity at the genotypic and phenotypic levels will enable accelerated discovery of more efficient treatments for patients and improve outcomes.
This study is not a clinical trial.
Interventions
- Other Biological Sample Collection
Excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
Primary outcome measures
- Implement organoid culture technologies. [Time frame: Baseline]
- Validate genotypic and phenotypic relevance of tumor-derived organoids for biobanking. [Time frame: Baseline]
- Establish functional testing using organoid cultures alone or in combination with additional cell types. [Time frame: Baseline]
- Perform drug testing and screens to identify new targets and/or new therapeutic strategies to effectively treat cancer. [Time frame: Baseline]
- Develop a Laboratory Developed Test (LDT) for CLEP/FDA approval that will inform clinicians of each patient's tumor responses to FDA approved drugs. [Time frame: Baseline]
- Develop stem cells from individual patient samples to study tumor evolution. [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- Adults ages 18 and older with a solid tumor cancer diagnosis.
- Adults ages 18 and older serving as healthy controls.
Exclusion criteria
- Human fetuses.
- Neonates.
- Children.
- Wards of the state.
- Prisoners.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Other
Study locations
United States · 1 center
- New York Stem Cell Foundation Research Institute — New York
Identifiers
NCT: NCT06350539 · 10-007